Keenova Therapeutics reported $517 million in net sales for Q2 2026, reflecting a $253 million increase year-over-year. The raised growth outlook for Acthar Gel to 20-22% signals strong Demand for its leading therapeutics, making it a compelling opportunity for investors.

Key Highlights

  • Acthar Gel net sales grew to $205 million, a 17% year-over-year increase, driven by strong demand.
  • Loss from continuing operations was $221 million, considerably higher than the $31 million loss in the previous year.
  • Keenova Therapeutics recorded net sales of $517 million for the second quarter of 2026, reflecting a substantial increase of $253 million compared to the same period last year.

Q2 Sales Surge to $517 Million

Keenova Therapeutics recorded net sales of $517 million for the second quarter of 2026, reflecting a substantial increase of $253 million compared to the same period last year. This impressive growth is primarily attributed to strong performances from Acthar Gel and XIAFLEX, which are key in the company's portfolio. Acthar Gel generated sales of $205 million, while XIAFLEX contributed another $150 million.

Despite the loss from continuing operations of $221 million, the overall sales increase indicates a solid demand for Keenova’s products. Investor interest is likely to grow given this strong Revenue trajectory.

Acthar Gel Sales Drive Growth

Acthar Gel sales alone reached $205 million, marking a 17% uptick year-over-year. This boost is a result of heightened patient demand, sales force effectiveness, and expanding market categories. The continued success of the SelfJect delivery system has further contributed to these numbers, attracting a wider patient base.

The projected growth for Acthar Gel now stands between 20% and 22% for the full year 2026, demonstrating the therapeutic's resilience in a competitive environment. Such promising forecasts enhance investor confidence moving forward.

XIAFLEX Pipeline Advancements

XIAFLEX net sales of $150 million were driven by increased demand, particularly in treatments for Peyronie’s disease. Keenova is advancing its pipeline with significant milestones, including positive Phase 3 data for a plantar fibromatosis study and plans to initiate a hammer toe study in Q3 2026. This progress, along with raised guidance for XIAFLEX sales growth to high single digits, is expected to enhance the company's long-term value proposition.

The clarity of these initiatives underscores the company's forward momentum.

Financial Guidance and Merger Synergies

Keenova anticipates overall pro forma net sales for 2026 to range between $1.94 billion and $2.00 billion, translating into a revised full-year outlook. Adjusted EBITDA is projected to be between $715 million and $745 million, bolstered by expected synergies realized through its recent merger with Endo. The company reported a realization of $25 million in synergies during Q2, highlighting efficient integration post-merger.

As synergies accumulate, investor sentiment could improve with enhanced profitability projections ahead.